Drug Profile
Human papilloma virus vaccine - Apimeds
Alternative Names: adeno-HPVVLP - ApimedsLatest Information Update: 14 Sep 2023
Price :
$50
*
At a glance
- Originator Apimeds
- Class Papillomavirus vaccines; Virus-like particle vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cervical cancer; Human papillomavirus infections
Most Recent Events
- 13 Sep 2023 Apimed's Patent protection for patent titled 'recombinant adenovirus vector producing human papillomavirus-like particles and live cervical cancer vaccine' in South Korea (No. 0785397) has ended
- 28 Aug 2020 No recent reports of development identified for preclinical development in Cervical-cancer(Prevention) in South Korea (Parenteral, Injection)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Human-papillomavirus-infections(Prevention) in South Korea (Parenteral, Injection)